Companies · Investment Vehicle
BRENTWOOD · Investment Vehicle · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on FCA Venture Partners VII, LP — recommendation, valuation, rhythm, risks.→FCA Venture Partners VII, LP has raised $8.8M over 1 round; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
FCA Venture Partners VII, LP behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
FCA Venture Partners VII, LP is one of 1793 Investment Vehicle companies tracked from BRENTWOOD. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Benchmarked against 1793 companies in Investment Vehicle. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 69% of sector peers (real $). Modeled value above 75% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $8.8M | 2021-07-01 | $39.8M | $98.2M | 90% |
| Series A | $4.1M | 2021-07-01 | $18.5M | $45.7M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Matthew A> King | — | 13 other | 2021-07 |
| JOHN R. BURCH, JR. | — | 6 other | 2021-07 |
| Nancy S. Allen | — | 6 other | 2021-07 |
| James A Patton | — | 4 other | 2021-07 |
| Andrew J Bouldin | — | 3 other | 2021-07 |
| Whitney L Haley | — | 3 other | 2021-07 |
| Whitney L Kalb | — | 1 other | 2021-07 |
FCA Venture Partners VII, LP is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| FCA Health Innovations II, LP | Healthtech | Series A | $8.5M | $167.8M | network6 shared operators · same stage |
| FCA Health Innovations II QP, LP | Healthtech | Series C | $55.1M | $1.3B | network6 shared operators |
| Entrada, Inc. | Other Health Care | Seed | $10.5M | $18.6M | network2 shared operators |
| Lumere, Inc. | Other Health Care | Series A | $6.3M | $100.5M | network1 shared operator · same stage |
| Catavolt, Inc. | Other Technology | Series A | $5.9M | $138.7M | network1 shared operator · same stage |
| MediQuire, Inc. | Other Technology | Series A | $4.9M | $135.2M | network1 shared operator · same stage |
| Enable Dental Inc. | Healthtech | Series A | $21.9M | $62.1M | network1 shared operator · same stage |
| ND Acquisitions Corp. | Pharmaceuticals | Series A | $51.6M | $119.2M | network1 shared operator · same stage |
See where FCA Venture Partners VII, LP sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at FCA Venture Partners VII, LP, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.